However, recent meta-analyses of only RCTs with samples varying from 464 to 7902 participants indicated no reduction of all-cause mortality and even higher risk of death in CKD patients including dialysis and predialysis with higher Hb target (>13 g/dL) than those with lower ones [8,9,22]. The gene discussed is GSTM1; the disease is chronic kidney disease.